Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

OBJECTIVE: While tocilizumab (TCZ) is known to increase low‐density lipoprotein (LDL) cholesterol levels, it is unclear whether TCZ increases cardiovascular risk in patients with rheumatoid arthritis (RA). This study was undertaken to compare the cardiovascular risk associated with receiving TCZ ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seoyoung C., Solomon, Daniel H., Rogers, James R., Gale, Sara, Klearman, Micki, Sarsour, Khaled, Schneeweiss, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573926/
https://www.ncbi.nlm.nih.gov/pubmed/28245350
http://dx.doi.org/10.1002/art.40084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573926/
https://www.ncbi.nlm.nih.gov/pubmed/28245350
http://dx.doi.org/10.1002/art.40084

Ejemplares similares